Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion

Clinical Lung Cancer

Volumn 18, Issue 3, 2017, Pages e219-e222

  Allen, Justin M ^a   Schrock, Alexa B ^a   Erlich, Rachel L ^a   Miller, Vincent A ^a   Stephens, Philip J ^a   Ross, Jeffrey S ^a   Ou, Sai Hong Ignatius ^b   Ali, Siraj M ^a   Vafai, Davood ^c  

^a FOUNDATION MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EISENHOWER MEDICAL CENTER   (United States)

Author keywords

Acquired resistance; ctDNA; EGFR mutation; FGFR3 fusion; Non small cell lung cancer

Indexed keywords

AFATINIB; CETUXIMAB; CIRCULATING TUMOR DNA; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; PEPTIDES AND PROTEINS; PROTEIN P63; TACC3 PROTEIN; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FGFR3 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; QUINAZOLINE DERIVATIVE; TACC3 PROTEIN, HUMAN;

AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DNA DETERMINATION; DNA EXTRACTION; DRUG DOSE REDUCTION; EXON; FEMALE; FUSION GENE; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN TISSUE; INTRON; LUNG ADENOCARCINOMA; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; SMOKING; TUMOR VOLUME; ADENOCARCINOMA; DRUG RESISTANCE; GENETICS; GENOME; LUNG TUMOR; METASTASIS; MUTATION; NON SMALL CELL LUNG CANCER; RECURRENT DISEASE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CETUXIMAB; CIRCULATING TUMOR DNA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENOME; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; NEOPLASM METASTASIS; ONCOGENE PROTEINS, FUSION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECURRENCE;

EID: 85008440507     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2016.12.006     Document Type: Article

References (22)

1. 1 Sequist, L.V., Bell, D.W., Lynch, T.J., Haber, D.A., Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25 (2007), 587–595.
2. 2 Yu, H.A., Arcila, M.E., Rekhtman, N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19 (2013), 2240–2247.
3. 3 Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011, 75ra26.
4. 4 Klempner, S.J., Bazhenova, L.A., Braiteh, F.S., et al. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI. Lung Cancer Amst Neth 89 (2015), 357–359.
5. 5 Liang, W., He, Q., Chen, Y., et al. Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report. BMC Cancer, 16, 2015, 62.
6. 6 Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
7. 7 Costa, R., Carneiro, B.A., Taxter, T., et al. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget 7 (2016), 55924–55938.
8. 8 Di Stefano, A.L., Fucci, A., Frattini, V., et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res 21 (2015), 3307–3317.
9. 9 Singh, D., Chan, J.M., Zoppoli, P., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337 (2012), 1231–1235.
10. 10 Williams, S.V., Hurst, C.D., Knowles, M.A., Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 22 (2013), 795–803.
11. 11 Wu, Y.-M., Su, F., Kalyana-Sundaram, S., et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3 (2013), 636–647.
12. 12 Doebele, R.C., Pilling, A.B., Aisner, D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18 (2012), 1472–1482.
13. 13 Redmond, K.L., Papafili, A., Lawler, M., Van Schaeybroeck, S., Overcoming resistance to targeted therapies in cancer. Semin Oncol 42 (2015), 896–908.
14. 14 Parker, B.C., Annala, M.J., Cogdell, D.E., et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 123 (2013), 855–865.
15. 15 Capelletti, M., Dodge, M.E., Ercan, D., et al. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer Res 20 (2014), 6551–6558.
16. 16 Kim, Y., Hammerman, P.S., Kim, J., et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 32 (2014), 121–128.
17. 17 Majewski, I.J., Mittempergher, L., Davidson, N.M., et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 230 (2013), 270–276.
18. 18 Wang, R., Wang, L., Li, Y., et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 20 (2014), 4107–4114.
19. 19 Crystal, A.S., Shaw, A.T., Sequist, L.V., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346 (2014), 1480–1486.
20. 20 Daly, C., Castanaro, C., Zhang, W., et al. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene, 2016, 1–11.
21. 21 Oliveras-Ferraros, C., Cufí, S., Queralt, B., et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer 106 (2012), 1406–1414.
22. 22 Ware, K.E., Marshall, M.E., Heasley, L.R., et al. Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS One, 5, 2010, e14117.